Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Georgia court approves T(2) settlement:

This article was originally published in Clinica

Executive Summary

The US District Court for the Northern District of Georgia has approved an agreement to settle a consolidated shareholder class action litigation involving T(2) Medical, a subsidiary of Coram Healthcare (Denver). The agreement, announced last October (see Clinica No 623, p 16), resolves litigation relating to claims asserted against T(2) Medical and certain of its former directors and officers, based on events which had occurred prior to the four-company merger which resulted in the formation of Coram. It states that Coram, on behalf of all defendants, will pay to the shareholder class $25 million in cash and will issue warrants to acquire an aggregate of 2.52 million shares of Coram common stock at an initial per-share exercise price of $20.25, subject to adjustment.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT091916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel